Media Contact October 28, 2026
Media Contact October 28, 2026 ────────────────────────────────────────────────────── Polly Manuel, 205 969-4532 [email protected] Investor Relations Contact Mark Miller, 205 970-5860 [email protected]
BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the third quarter ended September 30, 2026.
See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.
“We are very pleased with our performance for the third quarter, with revenue increasing 8.9% and Adjusted EBITDA growing 15.5%,” said Mark Tarr, President and Chief Executive Officer. “During the first nine months of 2026, we opened four hospitals totaling 189 beds and added 85 beds to existing hospitals, reflecting our commitment to meeting the growing demand for high-quality inpatient rehabilitation services. Our value proposition and disciplined operating strategy continue to be validated, and we remain highly optimistic about the long-term prospects of our business.”
Full-Year 2026 Guidance Previous Guidance Updated Guidance -In Millions, Except Per Share Data Net operating revenue $6,410 to $6,490 $6,450 to $6,500 Adjusted EBITDA $1,365 to $1,395 $1,395 to $1,415 Adjusted earnings per share from continuing operations $6.02 to $6.25 $6.23 to $6.37 attributable to Encompass Health
For considerations regarding the Company’s 2026 guidance, see the supplemental information posted on the Company’s website at http://investor.encompasshealth.com. See also the “Other information” section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.
The Company will host an investor conference call at 10:00 a.m. Eastern Time on Thursday, October 29, 2026 to discuss its results for the third quarter of 2026. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.
The conference call may be accessed by dialing 833 354-6854 and giving the conference ID EHCQ326. International callers should dial 785 838-9343 and give the same conference ID. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 179 hospitals in 39 states and Puerto Rico, the Company provides high- quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is recognized by Newsweek as America’s Most Awarded Leader in Inpatient Rehabilitation and is ranked among Fortune's World’s Most Admired Companies™ 1 and Forbes’ America’s Best Companies. It is also recognized by Becker’s Healthcare and Modern Healthcare as a top healthcare employer. For more information, visit encompasshealth.com, or follow us on our newsroom, X, Instagram and Facebook.
1 From Fortune. © 2026 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World’s Most Admired Companies™ is trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health.
The information in this press release is summarized and should be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “September 2026 Form 10-Q”), when filed, as well as the Company’s Current Report on Form 8-K filed on October 28, 2026 (the “Q3 Earnings Form 8-K”), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at http://investor.encompasshealth.com for reference during its October 29, 2026 earnings call.
The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q3 Earnings Form 8-K. Readers are encouraged to review the “Note Regarding Presentation of Non-GAAP Financial Measures” included in the Q3 Earnings Form 8-K which provides further explanation and disclosure regarding the Company’s use of these non-GAAP financial measures.
Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company’s results computed in accordance with GAAP.
However, the following reasonably estimable GAAP measures for 2026 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:
• Interest expense and amortization of debt discounts and fees - approximately $130 million
The Q3 Earnings Form 8-K and, when filed, the September 2026 Form 10-Q can be found on the Company’s website at http://investor.encompasshealth.com and the SEC's website at www.sec.gov.
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── -In Millions Assets Current assets: Cash and cash $ 76.2 $ 72.2 equivalents Restricted cash 24.0 30.7 Accounts 712.0 619.2 receivable Other current 200.8 183.8 assets Total current 1,013.0 905.9 assets Property and 4,477.6 4,101.6 equipment, net Operating lease right-of-use 194.5 212.6 assets Goodwill 1,323.5 1,317.6 Intangible 301.5 308.3 assets, net Other long-term 256.4 243.7 assets Total assets $ 7,566.5 $ 7,089.7 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term $ 47.8 $ 43.6 debt Current operating lease 28.0 26.5 liabilities Accounts payable 231.4 178.2 Accrued expenses and other 620.2 588.1 current liabilities Total current 927.4 836.4 liabilities Long-term debt, net of current 2,551.3 2,447.2 portion Long-term operating lease 176.3 196.6 liabilities Deferred income 127.5 126.8 tax liabilities Other long-term 222.8 206.9 liabilities Total 4,005.3 3,813.9 liabilities Commitments and contingencies Redeemable noncontrolling 58.6 58.3 interests Shareholders’ equity: Encompass Health shareholders’ 2,681.2 2,438.2 equity Noncontrolling 821.4 779.3 interests Total shareholders’ 3,502.6 3,217.5 equity Total liabilities and $ 7,566.5 $ 7,089.7 shareholders’ equity
Nine Months Ended September 30, Cash flows from 2026 operating activities: (In Millions) 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 659.2 $ 556.0 (Income) loss from discontinued -14.5 1.8 operations, net of tax Adjustments to reconcile net income to net cash provided by operating activities— Depreciation and 273.4 241.5 amortization Loss on early 3.4 — extinguishment of debt Stock-based compensation 40.3 38.1 Deferred tax expense 1.6 3.2 Gain on investments -21.8 -6.1 Other, net 9.7 7.2 Change in assets and liabilities, net of acquisitions— Accounts receivable -89.5 -18.8 Other assets -20.8 -19.5 Accounts payable 43.5 -32.7 Accrued payroll 13.6 6.4 Accrued interest payable -5.7 -15.8 Other liabilities 46.1 70.8 Net cash provided by (used in) operating 19.2 -2.5 activities of discontinued operations Total adjustments 313.0 271.8 Net cash provided by operating 957.7 829.6 activities Cash flows from investing activities: Purchases of property, equipment, and -617.2 -507.1 intangible assets Proceeds from sale of restricted 83.2 160.0 investments Purchases of restricted -79.7 -165.9 investments Other, net -13.6 -12.2 Net cash used in -627.3 -525.2 investing activities Cash flows from financing activities: Proceeds from bond 598.8 — issuance Principal payments on debt, including -414.5 -113.2 pre-payments Borrowings on revolving 745.0 140.0 credit facility Payments on revolving -800.0 -80.0 credit facility Principal payments under finance lease -19.7 -17.7 obligations Debt amendment and -13.9 — issuance costs Repurchases of common stock, including -203.7 -81.7 fees and expenses Dividends paid on common -57.9 -52.1 stock Distributions paid to noncontrolling -141.8 -109.4 interests of consolidated affiliates Taxes paid on behalf of employees for -30.9 -19.9 shares withheld Other, net 5.5 0.2 Net cash used in -333.1 -333.8 financing activities Decrease in cash, cash equivalents, and -2.7 -29.4 restricted cash Cash, cash equivalents, and restricted 102.9 123.1 cash at beginning of period Cash, cash equivalents, and restricted $ 100.2 $ 93.7 cash at end of period
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow
For the three months ended September 30, 2026, net cash used in investing activities was $241.6 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended September 30, 2026 was $153.7 million and resulted primarily from repurchases of common stock, distributions paid to noncontrolling interests of consolidated affiliates, net debt payments, and cash dividends paid on common stock.
For the three months ended September 30, 2025, net cash used in investing activities was $201.3 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended September 30, 2025 was $113.2 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, net debt payments, repurchases of common stock, and cash dividends paid on common stock.
For the nine months ended September 30, 2026 net cash used in investing activities was $627.3 million and resulted primarily from capital expenditures. Net cash used in financing activities during the nine months ended September 30, 2026 was $333.1 million and resulted primarily from repurchases of common stock, distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and taxes paid on behalf of employees for shares withheld partially offset by net debt borrowings.
For the nine months ended September 30, 2025, net cash used in investing activities was $525.2 million and resulted primarily from capital expenditures. Net cash used in financing activities during the nine months ended September 30, 2025 was $333.8 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, repurchases of common stock, net debt payments, and cash dividends paid on common stock.
Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the business, strategy, outlook, growth targets and guidance considerations, dividend strategies, effective income tax rates, cost trends, legislative and regulatory developments or their impacts, financial guidance, ability to return value to shareholders, projected capital expenditures, acquisition opportunities, development projects, addressable market size, other balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, possible reductions or other changes in Medicaid reimbursement, including Medicaid directed and supplemental payment programs and Medicaid waiver programs, which may decrease our revenues and increase our provider tax expenses; infectious disease outbreak, including the speed, depth, geographic reach and duration of its spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; Encompass Health's infectious disease prevention and control efforts; the demand for Encompass Health’s services, including based on any downturns in the economy and consumer confidence in patient care; the price of Encompass Health's common stock as it affects Encompass Health's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' or partners’ information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction and Encompass Health's ability to adapt operations to those changes, including in connection with the CMS inpatient rehabilitation review choice demonstration project; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis, including as part of the review choice demonstration; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing such as the transforming episode accountability model and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by infectious disease outbreaks, and the impact on Encompass Health's labor expenses from potential union activity, staffing shortages, and competitive compensation practices; general conditions in the economy and capital markets, including any instability or uncertainty related to trade war, armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in
the cost of, or the decrease in the availability of, construction materials and necessary supplies, including as a result of tariffs and import restrictions; the increase in the costs of defending and insuring against alleged professional liability claims, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2025 and Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, when filed.
Full text with the tables
Exhibit 99.1
Media Contact October 28, 2026
──────────────────────────────────────────────────────
Polly Manuel, 205 969-4532
[email protected]
Investor Relations Contact
Mark Miller, 205 970-5860
[email protected]
Encompass Health reports results for third quarter 2026
Increases full-year guidance
BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), the largest owner
and operator of inpatient rehabilitation hospitals in the United States, today
reported its results of operations for the third quarter ended September 30,
2026.
Summary results
Q3
2026
(In
Mil…
Exc…
Per
Sha… Q3 Gro…
Dat… 2025 Dol… Per…
──────────────────────────────────────────────────────────────────────────────
Net
op… $ 1,6… $ 1,4… $ 132.0 8.9 %
re…
In…
fr…
co…
op…
at…
to 1.51 1.24 0.27 21.8 %
En…
He…
per
di…
sh…
Ad…
ea… 1.52 1.23 0.29 23.6 %
per
sh…
Ca…
fl…
pr… 362… 270… 91.2 33.7 %
by
op…
ac…
Ad… 346… 300… 46.5 15.5 %
EB…
Ad…
fr… 263… 174… 89.2 51.2 %
ca…
fl…
(A…
Am…
Di… 69,… 65,8… 5.7 %
Sa…
di… 3.0 %
gr…
Net
pa…
re… $ 22,… $ 21,… 4.0 %
per
di…
See attached supplemental information for calculations of non-GAAP measures and
reconciliations to their most comparable GAAP measure.
“We are very pleased with our performance for the third quarter, with revenue
increasing 8.9% and Adjusted EBITDA growing 15.5%,” said Mark Tarr, President
and Chief Executive Officer. “During the first nine months of 2026, we opened
four hospitals totaling 189 beds and added 85 beds to existing hospitals,
reflecting our commitment to meeting the growing demand for high-quality
inpatient rehabilitation services. Our value proposition and disciplined
operating strategy continue to be validated, and we remain highly optimistic
about the long-term prospects of our business.”
1
2026 Guidance
The Company increased its full-year guidance as follows:
Full-Year 2026 Guidance
Previous Guidance Updated Guidance
-In Millions, Except Per
Share Data
Net operating revenue $6,410 to $6,490 $6,450 to $6,500
Adjusted EBITDA $1,365 to $1,395 $1,395 to $1,415
Adjusted earnings per
share from
continuing operations $6.02 to $6.25 $6.23 to $6.37
attributable to
Encompass Health
For considerations regarding the Company’s 2026 guidance, see the supplemental
information posted on the Company’s website at
http://investor.encompasshealth.com. See also the “Other information” section
below for an explanation of why the Company does not provide guidance for
comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.
Earnings conference call and webcast
The Company will host an investor conference call at 10:00 a.m. Eastern Time on
Thursday, October 29, 2026 to discuss its results for the third quarter of 2026.
For reference during the call, the Company will post certain supplemental
information at http://investor.encompasshealth.com.
The conference call may be accessed by dialing 833 354-6854 and giving the
conference ID EHCQ326. International callers should dial 785 838-9343 and give
the same conference ID. Please call approximately ten minutes before the start
of the call to ensure you are connected. The conference call will also be
webcast live and will be available for on-line replay at
http://investor.encompasshealth.com by clicking on an available link.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient
rehabilitation hospitals in the United States. With a national footprint that
includes 179 hospitals in 39 states and Puerto Rico, the Company provides high-
quality, compassionate rehabilitative care for patients recovering from a major
injury or illness, using advanced technology and innovative treatments to
maximize recovery. Encompass Health is recognized by Newsweek as America’s Most
Awarded Leader in Inpatient Rehabilitation and is ranked among Fortune's World’s
Most Admired Companies™ 1 and Forbes’ America’s Best Companies. It is also
recognized by Becker’s Healthcare and Modern Healthcare as a top healthcare
employer. For more information, visit encompasshealth.com, or follow us on our
newsroom, X, Instagram and Facebook.
1 From Fortune. © 2026 Fortune Media IP Limited. All rights reserved. Fortune®
is a registered trademark and Fortune World’s Most Admired Companies™ is
trademark of Fortune Media IP Limited and are used under license. Fortune and
Fortune Media IP Limited are not affiliated with, and do not endorse products or
services of, Encompass Health.
2
Other information
The information in this press release is summarized and should be read in
conjunction with the Company’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2026 (the “September 2026 Form 10-Q”), when filed, as well
as the Company’s Current Report on Form 8-K filed on October 28, 2026 (the “Q3
Earnings Form 8-K”), to which this press release is attached as Exhibit 99.1. In
addition, the Company will post supplemental information today on its website at
http://investor.encompasshealth.com for reference during its October 29, 2026
earnings call.
The financial data contained in the press release and supplemental information
include non-GAAP financial measures, including the Company’s adjusted earnings
per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow.
Reconciliations to their most comparable GAAP measure, except with regard to
non-GAAP guidance, are included below or in the Q3 Earnings Form 8-K. Readers
are encouraged to review the “Note Regarding Presentation of Non-GAAP Financial
Measures” included in the Q3 Earnings Form 8-K which provides further
explanation and disclosure regarding the Company’s use of these non-GAAP
financial measures.
Excluding net operating revenues, the Company does not provide guidance on a
GAAP basis because it is unable to predict, with reasonable certainty, the
future impact of items that are deemed to be outside the control of the Company
or otherwise not indicative of its ongoing operating performance. Such items
include government, class action, and related settlements; professional
fees—accounting, tax, and legal; mark-to-market adjustments for stock
appreciation rights; gains or losses related to hedging instruments; loss on
early extinguishment of debt; adjustments to its income tax provision (such as
valuation allowance adjustments and settlements of income tax claims); items
related to corporate and facility restructurings; and certain other items the
Company believes to be not indicative of its ongoing operations. These items
cannot be reasonably predicted and will depend on several factors, including
industry and market conditions, and could be material to the Company’s results
computed in accordance with GAAP.
However, the following reasonably estimable GAAP measures for 2026 would be
included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP
measures could be reasonably predicted:
• Interest expense and amortization of debt discounts and fees - approximately
$130 million
• Amortization of debt-related items - approximately $10 million
The Q3 Earnings Form 8-K and, when filed, the September 2026 Form 10-Q can be
found on the Company’s website at http://investor.encompasshealth.com and the
SEC's website at www.sec.gov.
3
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited)
Thr…
Mon…
End…
Sep…
30,
2026
(In Nine
Mil… Mon…
Exc… End…
Per Sep…
Sha… 30,
Dat… 20… 2026 20…
──────────────────────────────────────────────────────────────────────────────
N…
o… $ 1,… $ 1,4… $ 4,… $ 4,3…
r…
O…
e…
S…
a… 84… 784… 2,… 2,3…
b…
O…
o… 24… 231… 74… 662…
e…
O… 15… 14.9 44… 44.5
c…
S… 65… 64.6 19… 189…
G…
a… 59… 56.1 18… 167…
a…
e…
D…
a… 95… 82.4 27… 241…
a…
T…
o… 1,… 1,2… 3,… 3,6…
e…
L…
on
e… — — 3.4 —
e…
of
d…
I…
e…
a…
a…
of 32… 30.8 96… 93.0
d…
d…
a…
f…
O… -1… -5.9 -2… -15…
i…
E…
in
n…
i… -0… -1.2 -0… -3.5
of
n…
a…
I…
f…
c…
o… 25… 219… 80… 695…
b…
i…
t…
e…
P…
f…
i… 53… 44.9 16… 137…
t…
e…
I…
f… 20… 175… 64… 557…
c…
o…
(…
i…
f…
d… -0… -0.4 14… -1.8
o…
n…
of
t…
N… 20… 174… 65… 556…
i…
L…
N…
i…
a… -5… -48… -1… -13…
to
n…
i…
N…
i…
a… $ 14… $ 126… $ 49… $ 420…
to
E…
H…
W…
a…
c…
s…
o…
B… 98.3 10… 98.8 10…
D… 99.7 10… 100… 10…
E…
p…
c…
s…
B…
e…
p…
s…
a…
to
E…
H…
c…
s…
C… $ 1.… $ 1.26 $ 4.… $ 4.19
o…
D… -0… — 0.… -0.…
o…
N… $ 1.… $ 1.26 $ 5.… $ 4.17
i…
D…
e…
p…
s…
a…
to
E…
H…
c…
s…
C… $ 1.… $ 1.24 $ 4.… $ 4.13
o…
D… -0… — 0.… -0.…
o…
N… $ 1.… $ 1.24 $ 4.… $ 4.11
i…
A…
a…
to
E…
H…
c…
s…
I…
f… $ 15… $ 126… $ 48… $ 421…
c…
o…
(…
i…
f…
d… -0… -0.4 14… -1.8
o…
n…
of
t…
N…
i…
a… $ 14… $ 126… $ 49… $ 420…
to
E…
H…
4
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
September 30,
2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
-In Millions
Assets
Current assets:
Cash and cash $ 76.2 $ 72.2
equivalents
Restricted cash 24.0 30.7
Accounts 712.0 619.2
receivable
Other current 200.8 183.8
assets
Total current 1,013.0 905.9
assets
Property and 4,477.6 4,101.6
equipment, net
Operating lease
right-of-use 194.5 212.6
assets
Goodwill 1,323.5 1,317.6
Intangible 301.5 308.3
assets, net
Other long-term 256.4 243.7
assets
Total assets $ 7,566.5 $ 7,089.7
Liabilities and
Shareholders’
Equity
Current
liabilities:
Current portion
of long-term $ 47.8 $ 43.6
debt
Current
operating lease 28.0 26.5
liabilities
Accounts payable 231.4 178.2
Accrued expenses
and other 620.2 588.1
current
liabilities
Total current 927.4 836.4
liabilities
Long-term debt,
net of current 2,551.3 2,447.2
portion
Long-term
operating lease 176.3 196.6
liabilities
Deferred income 127.5 126.8
tax liabilities
Other long-term 222.8 206.9
liabilities
Total 4,005.3 3,813.9
liabilities
Commitments and
contingencies
Redeemable
noncontrolling 58.6 58.3
interests
Shareholders’
equity:
Encompass Health
shareholders’ 2,681.2 2,438.2
equity
Noncontrolling 821.4 779.3
interests
Total
shareholders’ 3,502.6 3,217.5
equity
Total
liabilities and $ 7,566.5 $ 7,089.7
shareholders’
equity
5
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended
September 30,
Cash flows from 2026
operating activities: (In Millions) 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 659.2 $ 556.0
(Income) loss from
discontinued -14.5 1.8
operations, net of tax
Adjustments to reconcile
net income to
net cash provided by
operating
activities—
Depreciation and 273.4 241.5
amortization
Loss on early 3.4 —
extinguishment of debt
Stock-based compensation 40.3 38.1
Deferred tax expense 1.6 3.2
Gain on investments -21.8 -6.1
Other, net 9.7 7.2
Change in assets and
liabilities, net of
acquisitions—
Accounts receivable -89.5 -18.8
Other assets -20.8 -19.5
Accounts payable 43.5 -32.7
Accrued payroll 13.6 6.4
Accrued interest payable -5.7 -15.8
Other liabilities 46.1 70.8
Net cash provided by
(used in) operating 19.2 -2.5
activities of
discontinued operations
Total adjustments 313.0 271.8
Net cash provided by
operating 957.7 829.6
activities
Cash flows from
investing activities:
Purchases of property,
equipment, and -617.2 -507.1
intangible assets
Proceeds from sale of
restricted 83.2 160.0
investments
Purchases of restricted -79.7 -165.9
investments
Other, net -13.6 -12.2
Net cash used in -627.3 -525.2
investing activities
Cash flows from
financing activities:
Proceeds from bond 598.8 —
issuance
Principal payments on
debt, including -414.5 -113.2
pre-payments
Borrowings on revolving 745.0 140.0
credit facility
Payments on revolving -800.0 -80.0
credit facility
Principal payments under
finance lease -19.7 -17.7
obligations
Debt amendment and -13.9 —
issuance costs
Repurchases of common
stock, including -203.7 -81.7
fees and expenses
Dividends paid on common -57.9 -52.1
stock
Distributions paid to
noncontrolling -141.8 -109.4
interests of
consolidated affiliates
Taxes paid on behalf of
employees for -30.9 -19.9
shares withheld
Other, net 5.5 0.2
Net cash used in -333.1 -333.8
financing activities
Decrease in cash, cash
equivalents, and -2.7 -29.4
restricted cash
Cash, cash equivalents,
and restricted 102.9 123.1
cash at beginning of
period
Cash, cash equivalents,
and restricted $ 100.2 $ 93.7
cash at end of period
6
Encompass Health Corporation and Subsidiaries
Supplemental Information
Earnings Per Share
Thr…
Mon…
End…
Sep…
30,
2026
(In Nine
Mil… Mon…
Exc… End…
Per Sep…
Sha… 30,
Dat… 20… 2026 20…
──────────────────────────────────────────────────────────────────────────────
A… $ 34… $ 300… $ 1,… $ 932…
E…
D…
a… -9… -82… -2… -24…
a…
I…
e…
a…
a…
of -3… -30… -9… -93…
d…
d…
a…
f…
S… -1… -14… -4… -38…
c…
L…
on
d…
or -0… -1.9 -3… -2.4
i…
of
a…
20… 170… 62… 557…
I…
n…
i…
of
o…
o…
p…
L…
on
e… — — -3… —
e…
of
d…
S…
r…
c…
i… 1.5 — 1.5 —
on
n…
i…
C…
in
f…
m… -0… 1.1 1.9 2.1
v…
of
m…
s…
G…
on
s… — — 17… —
of
G…
K…
P… 20… 171… 64… 559…
i…
I…
t… -5… -44… -1… -13…
e…
I…
f… $ 15… $ 126… $ 48… $ 421…
c…
o…
B… 98.3 10… 98.8 10…
s…
D… 99.7 10… 100… 10…
s…
B…
e… $ 1.… $ 1.26 $ 4.… $ 4.19
p…
s…
D…
e… $ 1.… $ 1.24 $ 4.… $ 4.13
p…
s…
(1) Income from continuing operations attributable to Encompass Health
7
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share
Three Nine
Months Months
Ended Ended
September September
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Earnings
per
share, $ 1.51 $ 1.24 $ 4.83 $ 4.13
as
reported
Adjustm…
net of
tax:
State
regulat… 0.01 — 0.01 —
change
impact
Income
tax — — -0.05 -0.12
adjustm…
Loss on
early — — 0.02 —
extingu…
of debt
Change
in fair
market — -0.01 -0.01 -0.01
value of
marketa…
securit…
Gain on
sale of — — -0.13 —
Gamma
Knife
Adjusted
earnings $ 1.52 $ 1.23 $ 4.67 $ 3.99
per
share*
* Adjusted EPS may not sum due to rounding.
8
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA
Three
Months
Ended Nine
Septem… Months
30, Ended
2026 Septemb…
(In 30,
Millio… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
provi… $ 362.0 $ 270.8 $ 957.7 $ 829.6
by
opera…
activ…
Inter…
expen…
and
amort…
of 32.2 30.8 96.8 93.0
debt
disco…
and
fees
(Loss)
gain
on -0.8 3.0 21.8 6.2
inves…
exclu…
impai…
Equity
in net
income 0.1 1.2 0.6 3.5
of
nonco…
affil…
Net
income
attri…
to
nonco… -53.7 -48.1 -160.9 -135.9
inter…
in
conti…
opera…
Amort…
of -2.1 -2.4 -6.7 -7.2
debt-…
items
Distr…
from -0.1 — -0.3 -1.4
nonco…
affil…
Curre…
porti…
of 57.2 47.0 161.8 134.3
income
tax
expen…
Change
in
assets -48.1 -1.8 12.8 9.6
and
liabi…
Cash
used
in
(prov…
by) 1.1 0.6 -19.2 2.5
opera…
activ…
of
disco…
opera…
State
regul…
change
impact -1.5 — -1.5 —
on
nonco…
inter…
Change
in
fair
market 0.3 -1.1 -1.9 -2.1
value
of
marke…
secur…
Gain
on
sale — — -17.5 —
of
Gamma
Knife
Other — 0.1 -0.1 0.2
Adjus… $ 346.6 $ 300.1 $ 1,043.4 $ 932.3
EBITDA
9
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass
Health per Diluted Share to Adjusted Earnings Per Share
For
the
Three
Months
Ended
Septe…
30,
2026
──────────────────────────────────────────────────────────────────────────────
Adjus…
Chan…
in
State Fair
As Regul… Mark… As
Repor… Change Value Adjus…
Impact of
Mark…
Secu…
-In
Milli…
Except
Per
Share
Amoun…
Adju… $ 346.6 $ — $ — $ 346.6
EBIT…
Depr…
and -95.7 2.9 — -92.8
amor…
Inte…
expe…
and
amor…
of -32.2 — — -32.2
debt
disc…
and
fees
Stoc… -15.0 — — -15.0
comp…
Loss
on
disp…
or -0.8 — — -0.8
impa…
of
asse…
State
regu…
chan…
impa… 1.5 -1.5 — —
on
nonc…
inte…
Chan…
in
fair
mark… -0.3 — 0.3 —
value
of
mark…
secu…
Inco…
from
cont…
oper… 204.1 1.4 0.3 205.8
befo…
inco…
tax
expe…
Prov…
for
inco… -53.4 -0.4 -0.1 -53.9
tax
expe…
Inco…
from
cont…
oper… $ 150.7 $ 1.0 $ 0.2 $ 151.9
attr…
to
Enco…
Heal…
Dilu…
earn…
per
share $ 1.51 $ 0.01 $ — $ 1.52
from
cont…
oper…
Dilu…
shar…
used 99.7
in
calc…
* Reconciliation to GAAP provided on page 9
** Adjusted EPS may not sum across due to rounding.
10
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass
Health per Diluted Share to Adjusted Earnings Per Share
For
the
Three
Mont…
Ended
Sept…
30,
2025
──────────────────────────────────────────────────────────────────────────────
Adjus…
Chan…
in
Income Fair
As Tax Mark… As
Repo… Adjus… Value Adjus…
of
Mark…
Secu…
-In
Mill…
Exce…
Per
Share
Amou…
Adj… $ 300.1 $ — $ — $ 300.1
EBI…
Dep…
and -82.4 — — -82.4
amo…
Int…
exp…
and
amo…
of -30.8 — — -30.8
debt
dis…
and
fees
Sto… -14.3 — — -14.3
com…
Loss
on
dis…
or -1.9 — — -1.9
imp…
of
ass…
Cha…
in
fair
mar… 1.1 — -1.1 —
val…
of
mar…
sec…
Inc…
from
con…
ope… 171.8 — -1.1 170.7
bef…
inc…
tax
exp…
Pro…
for
inc… -44.9 -0.2 0.3 -44.8
tax
exp…
Inc…
from
con…
ope… $ 126.9 $ -0.2 $ -0.8 $ 125.9
att…
to
Enc…
Hea…
Dil…
ear…
per
sha… $ 1.24 $ — $ -0.01 $ 1.23
from
con…
ope…
Dil…
sha…
used 102.3
in
cal…
* Reconciliation to GAAP provided on page 9
** Adjusted EPS may not sum across due to rounding.
11
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass
Health per Diluted Share to Adjusted Earnings Per Share
F…
t…
N…
M…
E…
S…
3…
2…
──────────────────────────────────────────────────────────────────────────────
A…
C…
L… in G…
S… on I… F… on
As R… E… T… M… S… As
R… C… E… A… V… of A…
I… of of G…
D… M… K…
S…
-…
M…
E…
P…
S…
A…
… $ 1… $ — $ — $ — $ — $ — $ 1,…
…
…
… -… 2… — — — — -2…
…
…
…
…
…
… -… — — — — — -9…
…
…
…
…
… -… — — — — — -4…
…
…
…
…
… -… — — — — — -3…
…
…
…
…
…
… -… — 3… — — — —
…
…
…
…
…
…
… 1… -… — — — — —
…
…
…
…
…
…
… 1… — — — -… — —
…
…
…
…
…
…
… 1… — — — — -… —
…
…
…
…
…
…
… 6… 1… 3… — -… -… 63…
…
…
…
…
…
…
… -… -… -… -… 0… 4… -1…
…
…
…
…
…
… $ 4… $ 1… $ 2… $ -… $ -… $ -… $ 46…
…
…
…
…
…
…
…
… $ 4… $ 0… $ 0… $ -… $ -… $ -… $ 4.…
…
…
…
…
…
… 1…
…
…
* Reconciliation to GAAP provided on page 9
** Adjusted EPS may not sum across due to rounding.
12
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass
Health per Diluted Share to Adjusted Earnings Per Share
For
the
Nine
Mont…
Ended
Sept…
30,
2025
──────────────────────────────────────────────────────────────────────────────
Adju…
Chan…
in
Inco… Fair
As Tax Mark… As
Repo… Adju… Value Adjus…
of
Mark…
Secu…
-In
Mill…
Exce…
Per
Share
Amou…
Adj… $ 932.3 $ — $ — $ 932.3
EBI…
Dep…
and -241… — — -241…
amo…
Int…
exp…
and
amo…
of -93.0 — — -93.0
debt
dis…
and
fees
Sto… -38.1 — — -38.1
com…
Loss
on
dis…
or -2.4 — — -2.4
imp…
of
ass…
Cha…
in
fair
mar… 2.1 — -2.1 —
val…
of
mar…
sec…
Inc…
from
con…
ope… 559.4 — -2.1 557.3
bef…
inc…
tax
exp…
Pro…
for
inc… -137… -11.8 0.6 -148…
tax
exp…
Inc…
from
con…
ope… $ 421.9 $ -11.8 $ -1.5 $ 408.6
att…
to
Enc…
Hea…
Dil…
ear…
per
sha… $ 4.13 $ -0.12 $ -0.01 $ 3.99
from
con…
ope…
Dil…
sha…
used 102.3
in
cal…
* Reconciliation to GAAP provided on page 9
** Adjusted EPS may not sum across due to rounding.
13
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Income to Adjusted EBITDA
Three
Months
Ended Nine
Septem… Months
30, Ended
2026 Septemb…
(In 30,
Millio… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 203.6 $ 174.6 $ 659.2 $ 556.0
income
Loss
(inco…
from
disco…
opera…
net of 0.8 0.4 -14.5 1.8
tax,
attri…
to
Encom…
Health
Net
income
attri…
to
nonco… -53.7 -48.1 -160.9 -135.9
inter…
inclu…
in
conti…
opera…
Provi…
for
income 53.4 44.9 163.4 137.5
tax
expen…
Inter…
expen…
and
amort…
of 32.2 30.8 96.8 93.0
debt
disco…
and
fees
Depre…
and 95.7 82.4 273.4 241.5
amort…
Loss
on
early — — 3.4 —
extin…
of
debt
Loss
on
dispo…
or 0.8 1.9 3.2 2.4
impai…
of
assets
Stock… 15.0 14.3 40.3 38.1
compe…
State
regul…
change
impact -1.5 — -1.5 —
on
nonco…
inter…
Change
in
fair
market 0.3 -1.1 -1.9 -2.1
value
of
marke…
secur…
Gain
on
sale — — -17.5 —
of
Gamma
Knife
Adjus… $ 346.6 $ 300.1 $ 1,043.4 $ 932.3
EBITDA
14
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free
Cash Flow
Three
Months
Ended Nine
Septem… Months
30, Ended
2026 Septemb…
(In 30,
Millio… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
provid… $ 362.0 $ 270.8 $ 957.7 $ 829.6
by
operat…
activi…
Impact
of 1.1 0.6 -19.2 2.5
discon…
operat…
Net
cash
provid…
by
operat… 363.1 271.4 938.5 832.1
activi…
of
contin…
operat…
Capital
expend… -56.0 -61.4 -166.0 -140.5
for
mainte…
Distri…
paid to
noncon…
intere… -43.7 -36.1 -141.8 -109.4
of
consol…
affili…
Items
not
indica…
of
ongoing
operat…
perfor…
Transa…
costs
and — 0.3 3.5 0.3
related
liabil…
Adjust…
free $ 263.4 $ 174.2 $ 634.2 $ 582.5
cash
flow
For the three months ended September 30, 2026, net cash used in investing
activities was $241.6 million and resulted primarily from capital expenditures.
Net cash used in financing activities during the three months ended September
30, 2026 was $153.7 million and resulted primarily from repurchases of common
stock, distributions paid to noncontrolling interests of consolidated
affiliates, net debt payments, and cash dividends paid on common stock.
For the three months ended September 30, 2025, net cash used in investing
activities was $201.3 million and resulted primarily from capital expenditures.
Net cash used in financing activities during the three months ended September
30, 2025 was $113.2 million and resulted primarily from distributions paid to
noncontrolling interests of consolidated affiliates, net debt payments,
repurchases of common stock, and cash dividends paid on common stock.
For the nine months ended September 30, 2026 net cash used in investing
activities was $627.3 million and resulted primarily from capital expenditures.
Net cash used in financing activities during the nine months ended September 30,
2026 was $333.1 million and resulted primarily from repurchases of common stock,
distributions paid to noncontrolling interests of consolidated affiliates, cash
dividends paid on common stock, and taxes paid on behalf of employees for shares
withheld partially offset by net debt borrowings.
For the nine months ended September 30, 2025, net cash used in investing
activities was $525.2 million and resulted primarily from capital expenditures.
Net cash used in financing activities during the nine months ended September 30,
2025 was $333.8 million and resulted primarily from distributions paid to
noncontrolling interests of consolidated affiliates, repurchases of common
stock, net debt payments, and cash dividends paid on common stock.
15
Encompass Health Corporation and Subsidiaries
Forward-Looking Statements
Statements contained in this press release and the supplemental information
which are not historical facts, such as those relating to the business,
strategy, outlook, growth targets and guidance considerations, dividend
strategies, effective income tax rates, cost trends, legislative and regulatory
developments or their impacts, financial guidance, ability to return value to
shareholders, projected capital expenditures, acquisition opportunities,
development projects, addressable market size, other balance sheet and cash flow
plans, are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. In addition, Encompass Health, through
its senior management, may from time to time make forward-looking public
statements concerning the matters described herein. All such estimates,
projections, and forward-looking information speak only as of the date hereof,
and Encompass Health undertakes no duty to publicly update or revise such
forward-looking information, whether as a result of new information, future
events, or otherwise. Such forward-looking statements are necessarily estimates
based upon current information and involve a number of risks and uncertainties.
Actual events or results may differ materially from those anticipated in these
forward-looking statements as a result of a variety of factors. While it is
impossible to identify all such factors, factors which could cause actual events
or results to differ materially from those estimated by Encompass Health
include, but are not limited to, possible reductions or other changes in
Medicaid reimbursement, including Medicaid directed and supplemental payment
programs and Medicaid waiver programs, which may decrease our revenues and
increase our provider tax expenses; infectious disease outbreak, including the
speed, depth, geographic reach and duration of its spread, which could decrease
our patient volumes and revenues and lead to staffing and supply shortages and
associated cost increases; Encompass Health's infectious disease prevention and
control efforts; the demand for Encompass Health’s services, including based on
any downturns in the economy and consumer confidence in patient care; the price
of Encompass Health's common stock as it affects Encompass Health's willingness
and ability to repurchase shares and the financial and accounting effects of any
repurchases; any adverse outcome of various lawsuits, claims, and legal or
regulatory proceedings involving Encompass Health, including any matters related
to yet undiscovered issues, if any, in acquired operations; Encompass Health's
ability to attract and retain key management personnel; potential disruptions,
breaches, or other incidents affecting the proper operation, availability, or
security of Encompass Health's or its vendors' or partners’ information systems,
including unauthorized access to or theft of patient, business associate, or
other sensitive information or inability to provide patient care because of
system unavailability; Encompass Health's ability to successfully complete and
integrate de novo developments, acquisitions, investments, and joint ventures
consistent with its growth strategy; increases in Medicare audit activity,
including increased use of sampling and extrapolation, resulting in additional
unpaid reimbursement claims and an increase in the backlog of appealed claims
denials; changes, delays in (including in connection with resolution of Medicare
payment reviews or appeals), or suspension of reimbursement for Encompass
Health's services by governmental or private payors; changes in the regulation
of the healthcare industry at either or both of the federal and state levels,
including as part of national healthcare reform and deficit reduction and
Encompass Health's ability to adapt operations to those changes, including in
connection with the CMS inpatient rehabilitation review choice demonstration
project; competitive pressures in the healthcare industry and Encompass Health's
response thereto; Encompass Health's ability to obtain and retain favorable
arrangements with third-party payors; Encompass Health's ability to control
costs, particularly labor and employee benefit costs, including group medical
expenses; adverse effects resulting from coverage determinations made by
Medicare Administrative Contractors regarding its Medicare reimbursement claims
and lengthening delays in Encompass Health's ability to recover improperly
denied claims through the administrative appeals process on a timely basis,
including as part of the review choice demonstration; Encompass Health's ability
to adapt to changes in the healthcare delivery system, including value-based
purchasing such as the transforming episode accountability model and involvement
in coordinated care initiatives or programs that may arise with its referral
sources; Encompass Health's ability to attract and retain nurses, therapists,
and other healthcare professionals in a highly competitive environment with
often severe staffing shortages, which may be worsened by infectious disease
outbreaks, and the impact on Encompass Health's labor expenses from potential
union activity, staffing shortages, and competitive compensation practices;
general conditions in the economy and capital markets, including any instability
or uncertainty related to trade war, armed conflict or an act of terrorism,
governmental impasse over approval of the United States federal budget, an
increase in the debt ceiling, or an international sovereign debt crisis; the
increase in
16
Encompass Health Corporation and Subsidiaries
Forward-Looking Statements
the cost of, or the decrease in the availability of, construction materials and
necessary supplies, including as a result of tariffs and import restrictions;
the increase in the costs of defending and insuring against alleged professional
liability claims, and Encompass Health's ability to predict the estimated costs
related to such claims; and other factors which may be identified from time to
time in Encompass Health's SEC filings and other public announcements, including
Encompass Health's Form 10‑K for the year ended December 31, 2025 and Form 10-Q
for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026,
when filed.
17